Conversion of N-(2-chloroethyl)-4-piperidinyl diphenylacetate (4-DAMP mustard) to an aziridinium ion and its interaction with muscarinic receptors in various tissues

EA Thomas, HH Hsu, MT Griffin, AL Hunter, T Luong and FJ Ehlert

Department of Pharmacology, College of Medicine, University of California, Irvine 92717.

A 2-chloroethylamine derivative [N-(2-chloroethyl)-4-piperidinyl diphenylacetate (4-DAMP mustard)] of the selective muscarinic antagonist N,N-dimethyl-4-piperidinyl diphenylacetate (4-DAMP) was synthesized, and its conversion to an aziridinium ion and interaction with muscarinic receptors was investigated. When dissolved in aqueous solution at pH 7.4 and 37 degrees, 4-DAMP mustard released an equivalent amount of chloride. The release of chloride was consistent with a first-order process having a half-time of 5.7 min. The aziridinium ion reached a peak concentration at 32 min, corresponding to 75% of the initial concentration of 4-DAMP mustard. When homogenates of rat brain, heart, and submaxillary gland were incubated with 4-DAMP mustard (9 nM) for 1 hr, washed extensively, and then assayed for muscarinic receptor binding properties, a 56% decrease in the binding capacity of N-[3H]methylscopolamine in the heart and brain and a 71% decrease in the gland were observed, without a significant change in the dissociation constants. The affinity of 4-DAMP mustard and its transformation products for muscarinic receptors was determined in competitive binding experiments with N-[3H] methylscopolamine, and the results show that the aziridinium ion of 4-DAMP mustard was the most potent form, compared with the parent 2-chloroethylamine (4-DAMP mustard) and the alcoholic hydrolysis product. The rates of receptor alkylation by 4-DAMP mustard were measured in the rat heart and gland. Virtually no alkylation (less than 1%) occurred in the heart at a 4- DAMP mustard concentration of 1.6 nM, after 30 min, whereas almost 50% alkylation was observed in the gland under the same conditions. Almost complete alkylation of receptors in the gland could be achieved at a 4- DAMP mustard concentration of 200 nM, after 1 hr. Treatment of the isolated rat ileum with 4-DAMP mustard caused an irreversible blockade of contractions elicited by the muscarinic agonist oxotremorine-M, and this blockade persisted after extensive washing. The results presented here show that 4-DAMP mustard forms an aziridinium ion that binds irreversibly to muscarinic receptors and exhibits selectivity for M3, compared with M2 muscarinic receptors.

Volume 41, Issue 4, pp. 718-726, 04/01/1992
Copyright © 1992 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				F. J. Ehlert and M. T. Griffin Two-State Models and the Analysis of the Allosteric Effect of Gallamine at the M2 Muscarinic Receptor J. Pharmacol. Exp. Ther., June 1, 2008; 325(3): 1039 - 1060. [Abstract] [Full Text] [PDF]

				M. T. Griffin, K. W. Figueroa, S. Liller, and F. J. Ehlert Estimation of Agonist Activity at G Protein-Coupled Receptors: Analysis of M2 Muscarinic Receptor Signaling through Gi/o,Gs, and G15 J. Pharmacol. Exp. Ther., June 1, 2007; 321(3): 1193 - 1207. [Abstract] [Full Text] [PDF]

				J. Bodenstein, D. P. Venter, and C. B. Brink Phenoxybenzamine and Benextramine, but Not 4-Diphenylacetoxy-N-[2-chloroethyl]piperidine Hydrochloride, Display Irreversible Noncompetitive Antagonism at G Protein-Coupled Receptors J. Pharmacol. Exp. Ther., August 1, 2005; 314(2): 891 - 905. [Abstract] [Full Text] [PDF]

				F. J. Ehlert, M. T. Griffin, D. M. Abe, T. H. Vo, M. M. Taketo, T. Manabe, and M. Matsui The M2 Muscarinic Receptor Mediates Contraction through Indirect Mechanisms in Mouse Urinary Bladder J. Pharmacol. Exp. Ther., April 1, 2005; 313(1): 368 - 378. [Abstract] [Full Text] [PDF]

				B. Rege, K. M. Carter, M. A. Sarkar, G. E. Kellogg, and W. H. Soine Irreversible Inhibition of CYP2D6 by (-)-Chloroephedrine, a Possible Impurity in Methamphetamine Drug Metab. Dispos., December 1, 2002; 30(12): 1337 - 1343. [Abstract] [Full Text] [PDF]

				B. Sarria, E. Naline, Y. Zhang, J. Cortijo, M. Molimard, J. Moreau, P. Therond, C. Advenier, and E. J. Morcillo Muscarinic M2 receptors in acetylcholine-isoproterenol functional antagonism in human isolated bronchus Am J Physiol Lung Cell Mol Physiol, November 1, 2002; 283(5): L1125 - L1132. [Abstract] [Full Text] [PDF]

				D. Shehnaz, K. Z. Ansari, and F. J. Ehlert Acetylcholine-Induced Desensitization of the Contractile Response to Histamine in Guinea Pig Ileum Is Prevented by Either Pertussis Toxin Treatment or by Selective Inactivation of Muscarinic M3 Receptors J. Pharmacol. Exp. Ther., June 1, 2001; 297(3): 1152 - 1159. [Abstract] [Full Text]

				D. D. Fraser, D. Doll, and B. A. MacVicar Serine/Threonine Protein Phosphatases and Synaptic Inhibition Regulate the Expression of Cholinergic-Dependent Plateau Potentials J Neurophysiol, March 1, 2001; 85(3): 1197 - 1205. [Abstract] [Full Text] [PDF]

				G. W. Sawyer and F. J. Ehlert Muscarinic M3 Receptor Inactivation Reveals a Pertussis Toxin-Sensitive Contractile Response in the Guinea Pig Colon: Evidence for M2/M3 Receptor Interactions J. Pharmacol. Exp. Ther., April 1, 1999; 289(1): 464 - 476. [Abstract] [Full Text]

				R. S. Ostrom and F. J. Ehlert Comparison of Functional Antagonism Between Isoproterenol and M2 Muscarinic Receptors in Guinea Pig Ileum and Trachea J. Pharmacol. Exp. Ther., March 1, 1999; 288(3): 969 - 976. [Abstract] [Full Text]

				R. S. Ostrom and F. J. Ehlert M2 Muscarinic Receptors Inhibit Forskolin- but not Isoproterenol-Mediated Relaxation in Bovine Tracheal Smooth Muscle J. Pharmacol. Exp. Ther., July 1, 1998; 286(1): 234 - 242. [Abstract] [Full Text]

				G. W. Sawyer and F. J. Ehlert Contractile Roles of the M2 and M3 Muscarinic Receptors in the Guinea Pig Colon J. Pharmacol. Exp. Ther., January 1, 1998; 284(1): 269 - 277. [Abstract] [Full Text]

				R. S. Ostrom and F. J. Ehlert M2 Muscarinic Receptor Inhibition of Agonist-induced Cyclic Adenosine Monophosphate Accumulation and Relaxation in the Guinea Pig Ileum J. Pharmacol. Exp. Ther., January 1, 1997; 280(1): 189 - 199. [Abstract] [Full Text]